4.7 Review

How I treat thrombocytopenia in pregnancy

Journal

BLOOD
Volume 121, Issue 1, Pages 38-47

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-08-448944

Keywords

-

Categories

Funding

  1. Amgen
  2. GlaxoSmithKline
  3. Nycomed
  4. Novo
  5. Bayer
  6. Baxter

Ask authors/readers for more resources

A mild thrombocytopenia is relatively frequent during pregnancy and has generally no consequences for either the mother or the fetus. Although representing no threat in the majority of patients, thrombocytopenia may result from a range of pathologic conditions requiring closer monitoring and possible therapy. Two clinical scenarios are particularly relevant for their prevalence and the issues relating to their management. The first is the presence of isolated thrombocytopenia and the differential diagnosis between primary immune thrombocytopenia and gestational thrombocytopenia. The second is thrombocytopenia associated with preeclampsia and its look-alikes and their distinction from thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. In this review, we describe a systematic approach to the diagnosis and treatment of these disease entities using a case presentation format. Our discussion includes the antenatal and perinatal management of both the mother and fetus. (Blood. 2013; 121(1): 38-47)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available